The etiological agents of the complex of South American arenaviral hemorrhagic fevers are a group of closely related New World mammarenaviruses (NWMs) including Junín, Machupo, Guanarito, Sabiá and Chapare. These viruses are maintained in nature through persistent infections of their respective host rodent species (Salazar-Bravo et al., 2002). Transmission of these agents to humans occurs through inhalation of aerosolized virus particles or contact with virus-containing rodent secreta or excreta (Childs et al., 1995). Junín virus (JUNV) is the most prevalent of pathogenic NWMs and is the etiological agent of Argentine hemorrhagic fever (AHF). AHF is an insidious disease characterized by severe hemorrhagic and/or neurologic manifestations with remittent fever, tremors, vascular leak and shock (de Bracco et al., 1978; Elsner et al., 1973; Enría et al., 1986; Enria et al., 2008). The pathogenesis of AHF is poorly understood; however, a salient feature of severe disease is an elevation in serum interferon-α (IFN-α) and other inflammatory mediators (Marta et al., 1999; Levis et al., 1984; Levis et al., 1985; Heller et al., 1992). The case-fatality rate of AHF can be as high as 30% in untreated individuals and the only countermeasures available for the prevention and treatment of severe JUNV infections are the Candid #1 vaccine and convalescent plasma (Enria et al., 2008). Neither has been approved for use outside of the area of endemicity and recent studies suggest that reversion to virulence by the vaccine virus can occur through a single nucleotide change in the envelope glycoprotein gene (York and Nunberg, 2018; Seregin et al., 2015; Albariño et al., 2011).

Animal models are essential to gaining insights into viral pathogenesis. Several species of non-human primates are susceptible to lethal JUNV disease (Kenyon et al., 1992; McKee et al., 1985; Avila et al., 1987). These models are considered the ‘gold standard’ because JUNV infection in these species more closely recapitulates the human disease. However, these models are costly and require specialized primate housing facilities within maximum biocontainment. Few small-animal models for JUNV exist because most standard laboratory rodent species, such as mice and hamsters, are refractory to severe disease. The most commonly used rodent model for JUNV is the guinea pig, which has served as the primary animal model to investigate pathogenesis and for screening promising therapeutic interventions (Yun et al., 2008; Gowen et al., 2013; Zeitlin et al., 2016). However, the use of this model for investigations into JUNV pathogenesis and countermeasure development has been mired by the lack of commercial reagents for this species.

A feature specific to the pathogenic NWMs is the use of human transferrin receptor 1 (hTfR1) for cellular entry (Radoshitzky et al., 2007; Helguera et al., 2012). In addition, different species known to be susceptible to disease following challenge with pathogenic NWMs express TfR1 orthologs that bind the viral envelope glycoprotein facilitating entry (Helguera et al., 2012; Hickerson et al., 2020). These findings suggest that the use of TfR1 for viral attachment and entry is an important determinant in defining whether a NWM can cause severe disease in a species other than the respective rodent reservoir host. Based on this, we investigated whether the expression of hTfR1 in laboratory mice would render them susceptible to lethal disease following JUNV challenge. Here, we demonstrate that transgenic hTfR1 mice develop a lethal disease course when exposed to the pathogenic Romero strain of JUNV and characterize the natural history and pathogenesis of disease. We also show that the type I IFN response plays a central role in the development of severe JUNV infection and disease in mice expressing hTfR1. The development of the hTfR1 mouse model of JUNV infection provides a novel system to investigate viral pathogenesis and assess promising therapeutics.

The first step in the viral infection process is the interaction between the virion and its host cell receptor. Pathogenic NWMs infect cells of their natural rodent reservoir via the endogenous TfR1 (Zong et al., 2014; Radoshitzky et al., 2008). These viruses have, in addition, adapted to utilize hTfR1 as the principal entry receptor in human cells (Radoshitzky et al., 2007). Related NWMs that enter through TfR1-independent mechanisms do not cause disease in humans (Sarute and Ross, 2017). Moreover, species known to be susceptible to disease when challenged with pathogenic NWMs (guinea pigs, marmosets, macaques) express TfR1 orthologs capable of mediating attachment and cellular entry (Helguera et al., 2012; Hickerson et al., 2020). By contrast, species that are refractory to pathogenic NWM infection (laboratory mice and hamsters) express TfR1 orthologs that do not support virus entry (Hickerson et al., 2020; Radoshitzky et al., 2008). Taken together, these findings suggest that the ability of NWMs to use TfR1 for entry is an important determinant in defining species vulnerability to severe disease (Choe et al., 2011). In the present study, we tested the hypothesis that mice genetically engineered to express hTfR1 would be susceptible to disease following exposure to JUNV. While hTfR1 HET mice were more susceptible to moderate JUNV disease than their WT counterparts, the development of uniformly lethal disease required the homozygous expression of hTfR1. The more severe disease phenotype was likely due to higher levels of hTfR1 in the liver and other tissues in the hTfR1 HOM mice compared to hTfR1 HET littermates (Yu et al., 2014). The susceptibility of hTfR1 HOM mice to lethal JUNV infection was age-dependent as the animals developed resistance as they matured. Several mechanisms may be involved in the development of resilience to JUNV challenge including a reduction in target receptor expression levels as mice age (Hofer et al., 2008; Domellöf et al., 2014; Lönnerdal and Kelleher, 2007; Sciot et al., 1990) and the maturation of the immune response (Coulombié et al., 1986; Blejer et al., 1987; Blejer et al., 1986; Bruyns et al., 1976; Doria et al., 1978; D'Eustachio and Edelman, 1975; Landreth, 2002). Additional studies are needed to investigate the age-dependent susceptibility of hTfR1 mice to JUNV and other New World hemorrhagic fever mammarenaviruses.

The type I IFN response plays an important role in protecting the host against viral pathogens; however, recent studies in mice characterizing the pathogenesis of acute infection by lymphocytic choriomeningitis virus (LCMV), a related mammarenavirus, have shown that the response can also contribute to lethal disease (Oldstone et al., 2018; Baccala et al., 2014). In the natural history and pathogenesis study characterizing JUNV infection and disease in hTfR1 HOM mice, we found that serum levels of IFN-α began to spike on day 8 p.i., just before the onset of clinical disease signs. Notably, patients suffering from AHF have been found to have increased concentrations of circulating IFN-α, which is believed to contribute to the clinical disease manifestations (Levis et al., 1984; Levis et al., 1985). The type I IFN response (IFN-α and IFN-β), which is a critical element of the innate immune response to throttle viral infections prior to the development of the adaptive immune response, can also have a damaging effect on the host when elevated systemic levels of type I IFN persist (Lee and Ashkar, 2018; Sen, 2001). Type I IFN signaling can impair immune system function by enhancing the expression of immunosuppressive molecules and inducing immune cell apoptosis (Stifter and Feng, 2015), which has been shown to affect the development of an effective adaptive immune response and contributes to the inability of the host to resolve persistent LCMV infections (Teijaro et al., 2013; Wilson et al., 2013). In lethal NZB and FVB/N mouse infection models based on intravenous challenge with 2 × 10⁶ plaque-forming units of the Clone 13 (Cl13) LCMV variant, type I IFN was found to underlie the severe disease phenotype (Oldstone et al., 2018; Baccala et al., 2014). Similarly, in hTfR1 HOM mice lacking IFN-α/βR or IFN-α/β and -γ receptors, or hTfR1 HOM mice treated with mAbs that block the IFN-α/βR, we demonstrate the essential role of the type I IFN response in driving JUNV pathogenesis. Deletion of the CD8 T cell response also prevents lethality associated with LCMV Cl13 infection in NZB and FVB/N mice (Oldstone et al., 2018; Schnell et al., 2012). The role of cytotoxic and helper T cells in JUNV pathogenesis in hTfR1 was not defined in the present study, but comparisons to the NZB and FVB/N models are complicated by differences in mouse age and genetics, as well as the virus challenge route and infectious doses administered. With respect to the latter, the outcome of infection (persistence vs. immune-mediated lethality) with LCMV Cl13 in C57BL/6 mice could be manipulated by modifying the virus challenge dose (Waggoner et al., 2012; Cornberg et al., 2013).

Mammarenaviruses are well known for their ability to cause persistent infections in rodents. Despite the lack of observable disease in the absence of IFN-α/β or IFN-α/β and -γ receptors, or following temporary mAb blockade of the IFN-α/βR, JUNV was able to persist in hTfR1 mice for up to 28 days in multiple tissues. It is likely that in the absence of type I IFN signaling JUNV infection would persist for an extended period (60 days), similar to that observed in Cl13 LCMV-infected mice protected from lethal disease through mAb treatment to block IFN-α/βR signaling (Oldstone et al., 2018). Also of note, JUNV persisted in multiple tissues of IFN-α/β and -γR-deficient mice expressing native mouse TfR1, while viral persistence in IFN-α/βR-deficient mice expressing mouse TfR1 was only evident in the brain. Consistent with the antiviral role of IFN-γ (Schroder et al., 2004), the dual type I and type II IFN receptor deficiency was more permissive to persistence regardless of whether or not hTfR1 was present. Further studies investigating long-term persistence and whether JUNV is shed in fecal matter and urine are needed to shed light on the potential virus-host carrier state that may result from infection in hTfR1 mice with compromised type I IFN responses.

In humans, mammarenaviral hemorrhagic fever is generally associated with mild pathological changes (Paessler and Walker, 2013). JUNV infection in hTfR1 mice resulted in limited histologic lesion development observed only during advanced stages of disease. Cell death of splenic mononuclear cells was present in mice at 10 and 12 days p.i. This lesion has been observed in other animal models of JUNV infection and natural infection in humans (Weissenbacher et al., 1975; Kenyon et al., 1985; González et al., 1980; Carballal et al., 1981). In humans, JUNV has been detected in phagocytic cells but not lymphocytes (González et al., 1980). In hTfR1 mice, the presence of JUNV antigen in the spleen was detected mainly in the white pulp suggesting a cytopathic effect on mononuclear cells. Similar findings have also been observed in the guinea pig model for JUNV (Yun et al., 2008), which suggests that targeting of mononuclear phagocytes may be central to pathogenesis. Death of the hTfR1 mice was tentatively attributed to neutrophilic encephalitis with JUNV antigen detected in neurons. Encephalitis has been reported in primates and humans infected with JUNV (González et al., 1983; Weissenbacher et al., 1979). Increased vascular permeability and prominent histopathology are features observed with LCMV Cl13 infection in NZB and FVB/N mice that succumb from respiratory failure and shock (Oldstone et al., 2018; Baccala et al., 2014; Schnell et al., 2012; Puglielli et al., 1999). Additional studies are needed to determine whether vascular leak associated with excess and prolonged proinflammatory cytokine concentrations, including IFN-α, may also be contributing to the demise of the JUNV-infected hTfR1 HOM mice.

The use of hTfR1 as the primary cellular entry receptor renders the pathogenic NWMs vulnerable to the development of countermeasures that interfere with the interaction between the viral envelope glycoprotein GP1 attachment subunit and the host cell receptor. The region of hTfR1 that mediates binding to the ectodomain of GP1 is the apical domain, which is not involved in binding to the known principal ligands, transferrin and hemochromatosis protein (Cheng et al., 2004; Lawrence et al., 1999; Montemiglio et al., 2019), thus representing a potential host-directed therapeutic target to broadly inhibit infection by JUNV and other New World hemorrhagic fever mammarenaviruses. Recent advances to exploit this vulnerability include the identification of a mAb (ch128.1) and an aptamer that bind to the apical domain of hTfR1 and the development of an immunoadhesin with the sequence of white-throated woodrat TfR1 apical domain fused to the Fc region of an IgG which binds to pathogenic NWM GP1 (Helguera et al., 2012; Maier et al., 2016; Cohen-Dvashi et al., 2020). Until now, proof-of-concept experiments to determine whether the ch128.1 strategy would prove to be an effective host-directed therapeutic to broadly treat NWM hemorrhagic fever were not possible due to the lack of an appropriate small-animal model. The novel hTfR1 mouse JUNV infection model that we have developed will be a valuable system in which this type of specific intervention can be investigated due to the requirement of hTfR1. Moreover, the new mouse model also provides an alternative to evaluate experimental therapies that directly target attachment by JUNV and related pathogenic NWMs and benefits from the large number of validated mouse reagents to assess immunological parameters and other physiological processes. By comparison, studies using the guinea pig JUNV infection model are limited by a shortage of reagents, animal costs and the requirement for substantially higher quantities of investigational drugs, which is often a limiting factor during early stages of antiviral drug discovery and development.

In summary, our findings identify hTfR1-mediated entry and the type I IFN response as key factors in the development of lethal JUNV disease in mice. The development of the first mouse model of JUNV infection in immunocompetent mice will be useful for investigating JUNV pathogenesis and early preclinical development of promising therapeutic interventions including approaches that disrupt the pathogenic NWM GP1-hTfR1 apical domain interaction. In addition, the identification of the type I IFN response as a key element in the development of severe JUNV disease in hTfR1 mice further supports investigation and development of immune-modulating agents as potential therapies to limit disease severity in cases of AHF and other NWM hemorrhagic fevers.

All data generated or analyzed during this study are included in the manuscript.

1. 1. Albariño CG
   2. Bird BH
   3. Chakrabarti AK
   4. Dodd KA
   5. Flint M
   6. Bergeron E
   7. White DM
   8. Nichol ST

   (2011) The major determinant of attenuation in mice of the Candid1 vaccine for argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain

   Journal of Virology 85:10404–10408.

   https://doi.org/10.1128/JVI.00856-11

   • PubMed
   • Google Scholar
2. 1. Avila MM
   2. Samoilovich SR
   3. Laguens RP
   4. Merani MS
   5. Weissenbacher MC

   (1987) Protection of junín virus-infected marmosets by passive administration of immune serum: association with late neurologic signs

   Journal of Medical Virology 21:67–74.

   https://doi.org/10.1002/jmv.1890210109

   • PubMed
   • Google Scholar
3. 1. Baccala R
   2. Welch MJ
   3. Gonzalez-Quintial R
   4. Walsh KB
   5. Teijaro JR
   6. Nguyen A
   7. Ng CT
   8. Sullivan BM
   9. Zarpellon A
   10. Ruggeri ZM
   11. de la Torre JC
   12. Theofilopoulos AN
   13. Oldstone MB

   (2014) Type I interferon is a therapeutic target for virus-induced lethal vascular damage

   PNAS 111:8925–8930.

   https://doi.org/10.1073/pnas.1408148111

   • PubMed
   • Google Scholar
4. 1. Blejer JL
   2. Remesar MC
   3. Lerman GD
   4. Nejamkis MR

   (1986) Macrophage maturity and modulation of response to junín virus in infected rats

   Journal of Infectious Diseases 154:478–482.

   https://doi.org/10.1093/infdis/154.3.478

   • PubMed
   • Google Scholar
5. 1. Blejer JL
   2. Remesar MC
   3. Nejamkis MR

   (1987) Macrophages are involved in age-dependent resistance of rats to Junin virus infection

   Intervirology 27:117–120.

   https://doi.org/10.1159/000149729

   • PubMed
   • Google Scholar
6. 1. Bruyns C
   2. Urbain-Vansanten G
   3. Planard C
   4. Vos-Cloetens C
   5. Urbain J

   (1976) Ontogeny of mouse B lymphocytes and inactivation by antigen of early B lymphocytes

   PNAS 73:2462–2466.

   https://doi.org/10.1073/pnas.73.7.2462

   • PubMed
   • Google Scholar
7. 1. Carballal G
   2. Oubiña JR
   3. Rondinone SN
   4. Elsner B
   5. Frigerio MJ

   (1981) Cell-mediated immunity and lymphocyte populations in experimental argentine hemorrhagic fever (Junín virus)

   Infection and Immunity 34:323–327.

   https://doi.org/10.1128/IAI.34.2.323-327.1981

   • PubMed
   • Google Scholar
8. 1. Cheng Y
   2. Zak O
   3. Aisen P
   4. Harrison SC
   5. Walz T

   (2004) Structure of the human transferrin receptor-transferrin complex

   Cell 116:565–576.

   https://doi.org/10.1016/S0092-8674(04)00130-8

   • PubMed
   • Google Scholar
9. 1. Childs JE
   2. Mills JN
   3. Glass GE

   (1995) Rodent-Borne hemorrhagic fever viruses: a special risk for mammalogists?

   Journal of Mammalogy 76:664–680.

   https://doi.org/10.2307/1382739

   • Google Scholar
10. 1. Choe H
    2. Jemielity S
    3. Abraham J
    4. Radoshitzky SR
    5. Farzan M

    (2011) Transferrin receptor 1 in the zoonosis and pathogenesis of new world hemorrhagic fever arenaviruses

    Current Opinion in Microbiology 14:476–482.

    https://doi.org/10.1016/j.mib.2011.07.014

    • PubMed
    • Google Scholar
11. 1. Cohen-Dvashi H
    2. Amon R
    3. Agans KN
    4. Cross RW
    5. Borenstein-Katz A
    6. Mateo M
    7. Baize S
    8. Padler-Karavani V
    9. Geisbert TW
    10. Diskin R

    (2020) Rational design of universal immunotherapy for TfR1-tropic arenaviruses

    Nature Communications 11:67.

    https://doi.org/10.1038/s41467-019-13924-6

    • PubMed
    • Google Scholar
12. 1. Cornberg M
    2. Kenney LL
    3. Chen AT
    4. Waggoner SN
    5. Kim SK
    6. Dienes HP
    7. Welsh RM
    8. Selin LK

    (2013) Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8 T cell response

    Frontiers in Immunology 4:475.

    https://doi.org/10.3389/fimmu.2013.00475

    • PubMed
    • Google Scholar
13. 1. Coulombié FC
    2. Alché LE
    3. Lampuri JS
    4. Coto CE

    (1986) Role of Calomys musculinus peritoneal macrophages in age-related resistance to Junin virus infection

    Journal of Medical Virology 18:289–298.

    https://doi.org/10.1002/jmv.1890180311

    • PubMed
    • Google Scholar
14. 1. D'Eustachio P
    2. Edelman GM

    (1975) Frequency and avidity of specific antigen-binding cells in developing mice

    The Journal of Experimental Medicine 142:1078–1091.

    https://doi.org/10.1084/jem.142.5.1078

    • PubMed
    • Google Scholar
15. 1. de Bracco MM
    2. Rimoldi MT
    3. Cossio PM
    4. Rabinovich A
    5. Maiztegui JI
    6. Carballal G
    7. Arana RM

    (1978) Argentine hemorrhagic fever alterations of the complement system and anti-Junin-virus humoral response

    The New England Journal of Medicine 299:216–221.

    https://doi.org/10.1056/NEJM197808032990502

    • PubMed
    • Google Scholar
16. 1. Domellöf M
    2. Braegger C
    3. Campoy C
    4. Colomb V
    5. Decsi T
    6. Fewtrell M
    7. Hojsak I
    8. Mihatsch W
    9. Molgaard C
    10. Shamir R
    11. Turck D
    12. van Goudoever J
    13. ESPGHAN Committee on Nutrition

    (2014) Iron requirements of infants and toddlers

    Journal of Pediatric Gastroenterology and Nutrition 58:119–129.

    https://doi.org/10.1097/MPG.0000000000000206

    • PubMed
    • Google Scholar
17. 1. Doria G
    2. D'Agostaro G
    3. Poretti A

    (1978)

    Age-dependent variations of antibody avidity

    Immunology 35:601–611.

    • PubMed
    • Google Scholar
18. 1. Elsner B
    2. Schwarz E
    3. Mando OG
    4. Maiztegui J
    5. Vilches A

    (1973) Pathology of 12 fatal cases of argentine hemorrhagic fever

    The American Journal of Tropical Medicine and Hygiene 22:229–236.

    https://doi.org/10.4269/ajtmh.1973.22.229

    • PubMed
    • Google Scholar
19. 1. Emonet SF
    2. Seregin AV
    3. Yun NE
    4. Poussard AL
    5. Walker AG
    6. de la Torre JC
    7. Paessler S

    (2011) Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease

    Journal of Virology 85:1473–1483.

    https://doi.org/10.1128/JVI.02102-10

    • PubMed
    • Google Scholar
20. 1. Enría D
    2. Franco SG
    3. Ambrosio A
    4. Vallejos D
    5. Levis S
    6. Maiztegui J

    (1986) Current status of the treatment of argentine hemorrhagic fever

    Medical Microbiology and Immunology 175:173–176.

    https://doi.org/10.1007/BF02122443

    • PubMed
    • Google Scholar
21. 1. Enria DA
    2. Briggiler AM
    3. Sánchez Z

    (2008) Treatment of argentine hemorrhagic fever

    Antiviral Research 78:132–139.

    https://doi.org/10.1016/j.antiviral.2007.10.010

    • PubMed
    • Google Scholar
22. 1. Golden JW
    2. Hammerbeck CD
    3. Mucker EM
    4. Brocato RL

    (2015) Brocato RL: animal models for the study of Rodent-Borne hemorrhagic fever viruses: arenaviruses and hantaviruses

    BioMed Research International 2015:793257.

    https://doi.org/10.1155/2015/793257

    • PubMed
    • Google Scholar
23. 1. González PH
    2. Cossio PM
    3. Arana R
    4. Maiztegui JI
    5. Laguens RP

    (1980)

    Laguens RP: lymphatic tissue in argentine hemorrhagic fever pathologic features

    Archives of Pathology & Laboratory Medicine 104:250–254.

    • PubMed
    • Google Scholar
24. 1. González PH
    2. Laguens RP
    3. Frigerio MJ
    4. Calello MA
    5. Weissenbacher MC

    (1983) Junin virus infection of callithrix jacchus: pathologic features

    The American Journal of Tropical Medicine and Hygiene 32:417–423.

    https://doi.org/10.4269/ajtmh.1983.32.417

    • PubMed
    • Google Scholar
25. 1. Gowen BB
    2. Wong M-H
    3. Jung K-H
    4. Sanders AB
    5. Mendenhall M
    6. Bailey KW
    7. Furuta Y
    8. Sidwell RW

    (2007) In vitro and in vivo activities of T-705 against Arenavirus and Bunyavirus infections

    Antimicrobial Agents and Chemotherapy 51:3168–3176.

    https://doi.org/10.1128/AAC.00356-07

    • Google Scholar
26. 1. Gowen BB
    2. Juelich TL
    3. Sefing EJ
    4. Brasel T
    5. Smith JK
    6. Zhang L
    7. Tigabu B
    8. Hill TE
    9. Yun T
    10. Pietzsch C
    11. Furuta Y
    12. Freiberg AN

    (2013) Favipiravir (T-705) inhibits junín virus infection and reduces mortality in a guinea pig model of argentine hemorrhagic fever

    PLOS Neglected Tropical Diseases 7:e2614.

    https://doi.org/10.1371/journal.pntd.0002614

    • PubMed
    • Google Scholar
27. 1. Helguera G
    2. Jemielity S
    3. Abraham J
    4. Cordo SM
    5. Martinez MG
    6. Rodríguez JA
    7. Bregni C
    8. Wang JJ
    9. Farzan M
    10. Penichet ML
    11. Candurra NA
    12. Choe H

    (2012) An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic fever arenaviruses

    Journal of Virology 86:4024–4028.

    https://doi.org/10.1128/JVI.06397-11

    • PubMed
    • Google Scholar
28. 1. Heller MV
    2. Saavedra MC
    3. Falcoff R
    4. Maiztegui JI
    5. Molinas FC

    (1992) Increased tumor necrosis factor-alpha levels in argentine hemorrhagic fever

    Journal of Infectious Diseases 166:1203–1204.

    https://doi.org/10.1093/infdis/166.5.1203

    • PubMed
    • Google Scholar
29. 1. Hickerson BT
    2. Westover JB
    3. Wang Z
    4. Lee YM
    5. Gowen BB

    (2020) Guinea pig transferrin receptor 1 mediates cellular entry of junín virus and other pathogenic new world arenaviruses

    Journal of Virology 94:e01278-19.

    https://doi.org/10.1128/JVI.01278-19

    • PubMed
    • Google Scholar
30. 1. Hofer T
    2. Marzetti E
    3. Xu J
    4. Seo AY
    5. Gulec S
    6. Knutson MD
    7. Leeuwenburgh C
    8. Dupont-Versteegden EE

    (2008) Increased iron content and RNA oxidative damage in skeletal muscle with aging and disuse atrophy

    Experimental Gerontology 43:563–570.

    https://doi.org/10.1016/j.exger.2008.02.007

    • PubMed
    • Google Scholar
31. 1. Kenyon RH
    2. Green DE
    3. Peters CJ

    (1985) Effect of immunosuppression on experimental argentine hemorrhagic fever in guinea pigs

    Journal of Virology 53:75–80.

    https://doi.org/10.1128/JVI.53.1.75-80.1985

    • PubMed
    • Google Scholar
32. 1. Kenyon RH
    2. McKee KT
    3. Zack PM
    4. Rippy MK
    5. Vogel AP
    6. York C
    7. Meegan J
    8. Crabbs C
    9. Peters CJ

    (1992) Aerosol infection of rhesus macaques with Junin virus

    Intervirology 33:23–31.

    https://doi.org/10.1159/000150227

    • PubMed
    • Google Scholar
33. 1. Landreth KS

    (2002) Critical windows in development of the rodent immune system

    Human & Experimental Toxicology 21:493–498.

    https://doi.org/10.1191/0960327102ht287oa

    • PubMed
    • Google Scholar
34. 1. Lawrence CM
    2. Ray S
    3. Babyonyshev M
    4. Galluser R
    5. Borhani DW
    6. Harrison SC

    (1999) Crystal structure of the ectodomain of human transferrin receptor

    Science 286:779–782.

    https://doi.org/10.1126/science.286.5440.779

    • PubMed
    • Google Scholar
35. 1. Lee AJ
    2. Ashkar AA

    (2018) The dual nature of type I and type II interferons

    Frontiers in Immunology 9:2061.

    https://doi.org/10.3389/fimmu.2018.02061

    • PubMed
    • Google Scholar
36. 1. Levis SC
    2. Saavedra MC
    3. Ceccoli C
    4. Falcoff E
    5. Feuillade MR
    6. Enria DA
    7. Maiztegui JI
    8. Falcoff R

    (1984) Endogenous interferon in argentine hemorrhagic fever

    Journal of Infectious Diseases 149:428–433.

    https://doi.org/10.1093/infdis/149.3.428

    • PubMed
    • Google Scholar
37. 1. Levis SC
    2. Saavedra MC
    3. Ceccoli C
    4. Feuillade MR
    5. Enria DA
    6. Maiztegui JI
    7. Falcoff R

    (1985) Correlation between endogenous interferon and the clinical evolution of patients with argentine hemorrhagic fever

    Journal of Interferon Research 5:383–389.

    https://doi.org/10.1089/jir.1985.5.383

    • PubMed
    • Google Scholar
38. 1. Lönnerdal B
    2. Kelleher SL

    (2007) Iron metabolism in infants and children

    Food and Nutrition Bulletin 28:S491–S499.

    https://doi.org/10.1177/15648265070284S402

    • PubMed
    • Google Scholar
39. 1. Maier KE
    2. Jangra RK
    3. Shieh KR
    4. Cureton DK
    5. Xiao H
    6. Snapp EL
    7. Whelan SP
    8. Chandran K
    9. Levy M

    (2016) A new transferrin receptor aptamer inhibits new world hemorrhagic fever Mammarenavirus entry

    Molecular Therapy - Nucleic Acids 5:e321.

    https://doi.org/10.1038/mtna.2016.32

    • PubMed
    • Google Scholar
40. 1. Marta RF
    2. Montero VS
    3. Hack CE
    4. Sturk A
    5. Maiztegui JI
    6. Molinas FC

    (1999) Proinflammatory cytokines and elastase-alpha-1-antitrypsin in argentine hemorrhagic fever

    The American Journal of Tropical Medicine and Hygiene 60:85–89.

    https://doi.org/10.4269/ajtmh.1999.60.85

    • PubMed
    • Google Scholar
41. 1. McKee KT
    2. Mahlandt BG
    3. Maiztegui JI
    4. Eddy GA
    5. Peters CJ

    (1985) Experimental argentine hemorrhagic fever in rhesus macaques: viral strain-dependent clinical response

    Journal of Infectious Diseases 152:218–221.

    https://doi.org/10.1093/infdis/152.1.218

    • PubMed
    • Google Scholar
42. 1. Montemiglio LC
    2. Testi C
    3. Ceci P
    4. Falvo E
    5. Pitea M
    6. Savino C
    7. Arcovito A
    8. Peruzzi G
    9. Baiocco P
    10. Mancia F
    11. Boffi A
    12. des Georges A
    13. Vallone B

    (2019) Cryo-EM structure of the human ferritin-transferrin receptor 1 complex

    Nature Communications 10:1121.

    https://doi.org/10.1038/s41467-019-09098-w

    • PubMed
    • Google Scholar
43. 1. Oldstone MBA
    2. Ware BC
    3. Horton LE
    4. Welch MJ
    5. Aiolfi R
    6. Zarpellon A
    7. Ruggeri ZM
    8. Sullivan BM

    (2018) Lymphocytic choriomeningitis virus clone 13 infection causes either persistence or acute death dependent on IFN-1, cytotoxic T lymphocytes (CTLs), and host genetics

    PNAS 115:E7814–E7823.

    https://doi.org/10.1073/pnas.1804674115

    • PubMed
    • Google Scholar
44. 1. Paessler S
    2. Walker DH

    (2013) Pathogenesis of the viral hemorrhagic fevers

    Annual Review of Pathology: Mechanisms of Disease 8:411–440.

    https://doi.org/10.1146/annurev-pathol-020712-164041

    • PubMed
    • Google Scholar
45. 1. Puglielli MT
    2. Browning JL
    3. Brewer AW
    4. Schreiber RD
    5. Shieh WJ
    6. Altman JD
    7. Oldstone MB
    8. Zaki SR
    9. Ahmed R

    (1999) Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway

    Nature Medicine 5:1370–1374.

    https://doi.org/10.1038/70938

    • PubMed
    • Google Scholar
46. 1. Radoshitzky SR
    2. Abraham J
    3. Spiropoulou CF
    4. Kuhn JH
    5. Nguyen D
    6. Li W
    7. Nagel J
    8. Schmidt PJ
    9. Nunberg JH
    10. Andrews NC
    11. Farzan M
    12. Choe H

    (2007) Transferrin receptor 1 is a cellular receptor for new world haemorrhagic fever arenaviruses

    Nature 446:92–96.

    https://doi.org/10.1038/nature05539

    • PubMed
    • Google Scholar
47. 1. Radoshitzky SR
    2. Kuhn JH
    3. Spiropoulou CF
    4. Albariño CG
    5. Nguyen DP
    6. Salazar-Bravo J
    7. Dorfman T
    8. Lee AS
    9. Wang E
    10. Ross SR
    11. Choe H
    12. Farzan M

    (2008) Receptor determinants of zoonotic transmission of new world hemorrhagic fever arenaviruses

    PNAS 105:2664–2669.

    https://doi.org/10.1073/pnas.0709254105

    • PubMed
    • Google Scholar
48. 1. Reed LJ

    (1938) A simple method of estimating fifty percent endpoints

    American Journal of Hygiene 27:493–497.

    https://doi.org/10.1093/oxfordjournals.aje.a118408

    • Google Scholar
49. 1. Salazar-Bravo J
    2. Ruedas LA
    3. Yates TL

    (2002) Mammalian reservoirs of arenaviruses

    Current Topics in Microbiology and Immunology 262:25–63.

    https://doi.org/10.1007/978-3-642-56029-3_2

    • PubMed
    • Google Scholar
50. 1. Sarute N
    2. Ross SR

    (2017) New world arenavirus biology

    Annual Review of Virology 4:141–158.

    https://doi.org/10.1146/annurev-virology-101416-042001

    • PubMed
    • Google Scholar
51. 1. Schnell FJ
    2. Sundholm S
    3. Crumley S
    4. Iversen PL
    5. Mourich DV

    (2012) Lymphocytic choriomeningitis virus infection in FVB mouse produces hemorrhagic disease

    PLOS Pathogens 8:e1003073.

    https://doi.org/10.1371/journal.ppat.1003073

    • PubMed
    • Google Scholar
52. 1. Schroder K
    2. Hertzog PJ
    3. Ravasi T
    4. Hume DA

    (2004) Interferon-γ: an overview of signals, mechanisms and functions

    Journal of Leukocyte Biology 75:163–189.

    https://doi.org/10.1189/jlb.0603252

    • PubMed
    • Google Scholar
53. 1. Sciot R
    2. Verhoeven G
    3. Van Eyken P
    4. Cailleau J
    5. Desmet VJ

    (1990) Transferrin receptor expression in rat liver: immunohistochemical and biochemical analysis of the effect of age and iron storage

    Hepatology 11:416–427.

    https://doi.org/10.1002/hep.1840110313

    • PubMed
    • Google Scholar
54. 1. Sen GC

    (2001) Viruses and interferons

    Annual Review of Microbiology 55:255–281.

    https://doi.org/10.1146/annurev.micro.55.1.255

    • PubMed
    • Google Scholar
55. 1. Seregin AV
    2. Yun NE
    3. Miller M
    4. Aronson J
    5. Smith JK
    6. Walker AG
    7. Smith JN
    8. Huang C
    9. Manning JT
    10. de la Torre JC
    11. Paessler S

    (2015) The glycoprotein precursor gene of Junin virus determines the virulence of the Romero strain and the attenuation of the Candid #1 strain in a representative animal model of Argentine hemorrhagic fever

    Journal of Virology 89:5949–5956.

    https://doi.org/10.1128/JVI.00104-15

    • PubMed
    • Google Scholar
56. 1. Stifter SA
    2. Feng CG

    (2015) Interfering with immunity: detrimental role of type I IFNs during infection

    The Journal of Immunology 194:2455–2465.

    https://doi.org/10.4049/jimmunol.1402794

    • PubMed
    • Google Scholar
57. 1. Teijaro JR
    2. Ng C
    3. Lee AM
    4. Sullivan BM
    5. Sheehan KC
    6. Welch M
    7. Schreiber RD
    8. de la Torre JC
    9. Oldstone MB

    (2013) Persistent LCMV infection is controlled by blockade of type I interferon signaling

    Science 340:207–211.

    https://doi.org/10.1126/science.1235214

    • PubMed
    • Google Scholar
58. 1. Waggoner SN
    2. Cornberg M
    3. Selin LK
    4. Welsh RM

    (2012) Natural killer cells act as rheostats modulating antiviral T cells

    Nature 481:394–398.

    https://doi.org/10.1038/nature10624

    • Google Scholar
59. 1. Weissenbacher MC
    2. de Guerrero LB
    3. Boxaca MC

    (1975)

    Experimental biology and pathogenesis of junin virus infection in animals and man

    Bulletin of the World Health Organization 52:507–515.

    • PubMed
    • Google Scholar
60. 1. Weissenbacher MC
    2. Calello MA
    3. Colillas OJ
    4. Rondinone SN
    5. Frigerio MJ

    (1979) Argentine hemorrhagic fever: a primate model

    Intervirology 11:363–365.

    https://doi.org/10.1159/000149059

    • PubMed
    • Google Scholar
61. 1. Wilson EB
    2. Yamada DH
    3. Elsaesser H
    4. Herskovitz J
    5. Deng J
    6. Cheng G
    7. Aronow BJ
    8. Karp CL
    9. Brooks DG

    (2013) Blockade of chronic type I interferon signaling to control persistent LCMV infection

    Science 340:202–207.

    https://doi.org/10.1126/science.1235208

    • PubMed
    • Google Scholar
62. 1. York J
    2. Nunberg JH

    (2018) Epistastic Interactions within the Junín Virus Envelope Glycoprotein Complex Provide an Evolutionary Barrier to Reversion in the Live-Attenuated Candid#1 Vaccine

    Journal of Virology 92:e01682-17.

    https://doi.org/10.1128/JVI.01682-17

    • PubMed
    • Google Scholar
63. 1. Yu YJ
    2. Atwal JK
    3. Zhang Y
    4. Tong RK
    5. Wildsmith KR
    6. Tan C
    7. Bien-Ly N
    8. Hersom M
    9. Maloney JA
    10. Meilandt WJ
    11. Bumbaca D
    12. Gadkar K
    13. Hoyte K
    14. Luk W
    15. Lu Y
    16. Ernst JA
    17. Scearce-Levie K
    18. Couch JA
    19. Dennis MS
    20. Watts RJ

    (2014) Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

    Science Translational Medicine 6:ra154.

    https://doi.org/10.1126/scitranslmed.3009835

    • PubMed
    • Google Scholar
64. 1. Yun NE
    2. Linde NS
    3. Dziuba N
    4. Zacks MA
    5. Smith JN
    6. Smith JK
    7. Aronson JF
    8. Chumakova OV
    9. Lander HM
    10. Peters CJ
    11. Paessler S

    (2008) Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs

    The American Journal of Tropical Medicine and Hygiene 79:275–282.

    https://doi.org/10.4269/ajtmh.2008.79.275

    • PubMed
    • Google Scholar
65. 1. Zeitlin L
    2. Geisbert JB
    3. Deer DJ
    4. Fenton KA
    5. Bohorov O
    6. Bohorova N
    7. Goodman C
    8. Kim D
    9. Hiatt A
    10. Pauly MH
    11. Velasco J
    12. Whaley KJ
    13. Altmann F
    14. Gruber C
    15. Steinkellner H
    16. Honko AN
    17. Kuehne AI
    18. Aman MJ
    19. Sahandi S
    20. Enterlein S
    21. Zhan X
    22. Enria D
    23. Geisbert TW

    (2016) Monoclonal antibody therapy for Junin virus infection

    PNAS 113:4458–4463.

    https://doi.org/10.1073/pnas.1600996113

    • PubMed
    • Google Scholar
66. 1. Zong M
    2. Fofana I
    3. Choe H

    (2014) Human and host species transferrin receptor 1 use by north american arenaviruses

    Journal of Virology 88:9418–9428.

    https://doi.org/10.1128/JVI.01112-14

    • PubMed
    • Google Scholar

Acceptance summary:

Current animal models of arenavirus pathogenesis are either not particularly robust or lack broad tractability. This study establishes a new mouse model of lethal Junin virus infection that recapitulates many key features of Junin virus pathogenesis in humans and may have broad utility for the development of vaccines and therapeutics targeting this important human pathogen.

Decision letter after peer review:

Thank you for submitting your article "Type I interferon underlies severe disease associated with Junin virus infection in mice" for consideration by eLife. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Karla Kirkegaard as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Juan Carlos de la Torre (Reviewer #2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The New World mammarenavirus Junin (JUNV) is the causative agent of Argentine hemorrhagic fever (AHF), a disease endemic to the Pampas region of Argentina that is associated with severe clinical symptoms including hemorrhagic and neurological manifestations and a case fatality rate of 15-30% in patients who do not receive appropriate supportive treatment. In addition, JUNV possesses features that make it a credible biodefense threat. Therefore, the importance of developing vaccines and therapeutics to counteract JUNV infections and associated disease. The availability of a mouse model of JUNV infection would facilitate the development of therapeutics and vaccines against AHF disease, as well as a better understanding of the molecular and cellular bases underlying JUNV pathogenesis.

Here, the authors use transgenic mice expressing TfnR, a Junin virus entry factor, to establish an immunocompetent mouse model of Junin virus infection that recapitulates several disease outcomes observed in humans. Lethal disease in infected mouse was associated with increased type I interferon responses, demonstrating a key pathological feature of human disease in these mice. The pathogenic effects could be mitigated in mice lacking IFN receptors, or in mice treated with IFN receptor blocking antibody.

Essential revisions:

1) The authors state that type I IFN underlies disease in this mouse model, but this is only demonstrated in young mice. Was viremia and serum IFN levels ever examined in older mice? Are these older mice just not replicating the virus, or is the virus replicating, but the mice are not making IFN? If the latter, would recombinant IFN treatment + Junin virus synergize in older mice to give a lethal phenotype?

2) Tissue viral loads shown in Figure 7D and 8D provide no information regarding the contribution of viral loads to pathogenesis, because they were measured at the late time period and because controls are missing. To be meaningful, viral loads should be measured at 11 or 12 dpi including control groups: hTfR1+/+ (7D) and "Placebo Tx" (8D) groups. Related to this issue, the authors stated "in the absence of a type I IFN response during the acute JUNV infection period hTfR1+/+ mice failed to clear the virus despite no apparent signs of illness". For this to be true, viral loads should be compared to those of control groups. In addition, 6 or 3-4 mice in Figure 7 and 8, respectively, may provide statistically significant survival data, but when population variance is huge like the viral loads in Figure 7D and 8D, 3-6 mice is not nearly sufficient. In order to use right sample size, power and sample size calculation should be redone based on the preliminary data in 7D and 8D.

3) Although hTfR1+/+ mice and IFNa/bR-/- and IFNa/bgR-/- mice are in different genetic background, they were backcrossed only twice. The authors' conclusion of type I IFN response being the key element for JUNV pathogenesis is partially based on the data obtained using these mice with mosaic genetic background (Figure 7). Combined with the data in Figure 8, this conclusion may still be valid, but nonetheless the authors should indicate contaminating 129 genes could have contributed to the susceptibility to viral infection and tissue viral loads.

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Thank you for resubmitting your article "Type I interferon underlies severe disease associated with Junín virus infection in mice" for consideration by eLife. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Karla Kirkegaard as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as eLife papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

The responses provided by the authors are overall reasonable, and they have incorporated changes to the text of the revised version of the paper that address many, but not all, the criticisms raised during the review of the originally submitted paper.

Revisions:

In lieu of additional experiments to address outstanding questions, the reviewers request that the authors expand the Discussion along the following lines:

A general suggestion is for the authors to add some useful topic sentences to the Discussion and, most importantly, conclude with a discussion of any other viral infections for which type 1 interferons contribute to pathogenesis.

More specifically, the authors should provide a more elaborated comparison between the mouse model of lethal JUNV infection and the NZB and FVB mouse models of LCMV infection where type I interferon was shown to be a critical factor for fatal outcome of infection.

Essential revisions:

1) The authors state that type I IFN underlies disease in this mouse model, but this is only demonstrated in young mice. Was viremia and serum IFN levels ever examined in older mice? Are these older mice just not replicating the virus, or is the virus replicating, but the mice are not making IFN? If the latter, would recombinant IFN treatment + Junin virus synergize in older mice to give a lethal phenotype?

The questions posed by the reviewers are of great interest and will pursued in future studies. Because our focus was to develop and characterize a lethal disease model of JUNV infection in hTfR1 mice, we did not characterize the infection in older age groups of mice that were refractory to disease. With that said, the weight loss observed in the 5-week-old hTfR1 mice challenged with JUNV suggests that there was viral replication in the older mice, which would most likely be accompanied by type I IFN induction. Studies by Ross and coworkers (Lavanya et al., Sci Transl Med, 2013; Cuevas and Ross, J Virol, 2014) have shown that the attenuated JUNV Candid#1 vaccine strain can replicate in 4 and 8 to 10-week-old mice with spleen infectious virus titers present on days 8 and 7 p.i., respectively, suggesting that the more virulent JUNV Romero strain used in our studies would likely replicate to higher titers and for a longer period of time in older mice expressing hTfR1.

2) Tissue viral loads shown in Figure 7D and 8D provide no information regarding the contribution of viral loads to pathogenesis, because they were measured at the late time period and because controls are missing. To be meaningful, viral loads should be measured at 11 or 12 dpi including control groups: hTfR1+/+ (7D) and "Placebo Tx" (8D) groups.

Ideally, we would have liked to include additional animals in each group that would be euthanized just prior to when the control groups (hTfR1+/+ or Placebo Tx) would be expected to succumb for evaluation of serum and tissue viral loads. Due to our animal and mAb limitations, we were not able to add the additional viral load arms to the studies.

Although the D panels of Figures 7 and 8 do not provide information regarding the contributions of viral loads to the disease process, the data indicate that mice with compromised type I, or compromised type I and type II, IFN responses do not clear JUNV by the end of the 28-day study period. Further studies are needed to investigate long-term persistence which could provide insights into the virus-host reservoir relationship.

Related to this issue, the authors stated "in the absence of a type I IFN response during the acute JUNV infection period hTfR1+/+ mice failed to clear the virus despite no apparent signs of illness". For this to be true, viral loads should be compared to those of control groups.

This statement has been removed from the manuscript as part of the extensive revision. We now include the following statement. “Despite the lack of observable disease in the absence of IFN-α/β or IFN-α/β and γ receptors, or following temporary mAb blockade of the IFN-α/βR, JUNV was able to persist in hTfR1 mice for up to 28 days in multiple tissues.” (fourth to the last sentence of the second paragraph of the Discussion)

In addition, 6 or 3-4 mice in Figure 7 and 8, respectively, may provide statistically significant survival data, but when population variance is huge like the viral loads in Figure 7D and 8D, 3-6 mice is not nearly sufficient. In order to use right sample size, power and sample size calculation should be redone based on the preliminary data in 7D and 8D.

The purpose of the end-of-study sample collection was to qualitatively address the question of whether or not the surviving mice had cleared the JUNV infection. Future studies investigating longer-term persistence will be powered to determine statistical significance comparing titers from the different genotypes based on the findings reported in Panels 7D and 8D.

3) Although hTfR1+/+ mice and IFNa/bR-/- and IFNa/bgR-/- mice are in different genetic background, they were backcrossed only twice. The authors' conclusion of type I IFN response being the key element for JUNV pathogenesis is partially based on the data obtained using these mice with mosaic genetic background (Figure 7). Combined with the data in Figure 8, this conclusion may still be valid, but nonetheless the authors should indicate contaminating 129 genes could have contributed to the susceptibility to viral infection and tissue viral loads.

This is an excellent point. We have addressed this oversight by the addition of the following statement to the Results text. “Because of the hybrid background of the genotypic variants of mice used in the initial experiment to assess the role of the type I IFN response in JUNV pathogenesis, we could not rule out the contribution of genetic variation in susceptibility to JUNV infection, disease and persistence.” (first sentence of last paragraph of the Results section)

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Revisions:

In lieu of additional experiments to address outstanding questions, the reviewers request that the authors expand the Discussion along the following lines:

A general suggestion is for the authors to add some useful topic sentences to the Discussion and, most importantly, conclude with a discussion of any other viral infections for which type 1 interferons contribute to pathogenesis.

More specifically, the authors should provide a more elaborated comparison between the mouse model of lethal JUNV infection and the NZB and FVB mouse models of LCMV infection where type I interferon was shown to be a critical factor for fatal outcome of infection.

As suggested, we have added useful topic sentences to the Discussion.

Importantly, we have added text to paragraphs two, three and four of the Discussion, specifically elaborating on the comparison between the mouse JUNV infection model and the NZB and FVB mouse models of LCMV infection.

Author details

1. Brady T Hickerson

   Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, United States

   Present address

   Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, United States

   Contribution

   Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing - original draft, Writing - review and editing

   Competing interests

   No competing interests declared

2. Eric J Sefing

   Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, United States

   Contribution

   Investigation

   Competing interests

   No competing interests declared

3. Kevin W Bailey

   Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, United States

   Contribution

   Investigation

   Competing interests

   No competing interests declared

4. Arnaud J Van Wettere

   1. Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, United States
   2. Utah Veterinary Diagnostic Laboratory, Utah State University, Logan, United States

   Contribution

   Formal analysis, Visualization, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

5. Manuel L Penichet

   1. Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, United States
   2. Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, United States
   3. UCLA Molecular Biology Institute, Los Angeles, United States
   4. UCLA Jonsson Comprehensive Cancer Center, Los Angeles, United States
   5. UCLA AIDS Institute, Los Angeles, United States

   Contribution

   Conceptualization, Resources, Formal analysis, Funding acquisition, Investigation, Methodology, Writing - review and editing

   Competing interests

   is a shareholder of Klyss Biotech, Inc. The Regents of the University of California licensed Dr. Penichet’s technology to this firm. The author has no other competing interests to declare.

6. Brian B Gowen

   Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, United States

   Contribution

   Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing

   For correspondence

   brian.gowen@usu.edu

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-9113-2575

• 1,150

  Page views

• 137

  Downloads

• 4

  Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.